相关实验视频
Updated: Jun 5, 2025

05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
37.1K
使用各种抗抑郁药的患者的2型糖尿病的短期风险与使用弗卢克塞丁的患者相比
1Department of Psychiatry, Keimyung University School of Medicine, Daegu, Korea.
Psychiatry and clinical psychopharmacology
|December 4, 2024
概括
某些抗抑郁药物,特别是米尔纳西普兰和文拉法辛,与与素相比,与患2型糖尿病 (T2D) 的短期风险有关. 其他抗抑郁药对T2D风险没有显著差异.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 临床医学 临床医学
背景情况:
- 抗抑郁药 (ADs) 已被广泛使用,但其潜在的代谢副作用,如患2型糖尿病 (T2D) 的风险,需要进行调查.
- 了解不同类别的AD中T2D的比较风险对于患者安全和知情的处方实践至关重要.
研究的目的:
- 在开始服用各种抗抑郁药 (ADs) 的患者中,比较一年内发展2型糖尿病 (T2D) 的短期风险.
- 用素作为对照组来评估与其他抗抑郁症相关的T2D相对风险,不包括三环抗抑郁药.
主要方法:
- 一项大规模的回顾性队列研究利用医疗保险审查和评估服务索赔数据来自1,456,489名患者.
- 纳入标准:年龄≥10岁,没有先前使用AD或糖尿病史的患者,在2017年1月至2017年12月期间开始AD.
- 考克斯的比例危险模型被用来计算T2D发病率的危险比率 (HRs),比较不同的ADs与素.
主要成果:
- 米尔纳西普兰 (HR:1.29,P=.03) 和芬拉法辛 (HR:1.22,P=.02) 与相比于素,与T2D的短期风险显著增加有关.
- 与fluoxetine相比,布普罗,蒂安尼普丁,埃斯基塔洛普拉姆,帕罗克塞丁,弗卢瓦克萨明,沃尔蒂奥克塞丁,塞特拉林,杜洛克赛丁和米尔塔扎在T2D风险上没有显示出统计学上显著的差异.
- 非显著组的P值在0.05到0.99之间,这表明这些代理商的T2D风险没有显著上升.
结论:
- 该研究将米尔纳西普兰和文拉法辛确定为抗抑郁药,与短期患2型糖尿病风险增加有关.
- 临床医生应考虑到这些发现,并在处方米尔纳西普兰和文拉法辛时谨慎行事,特别是在患有T2D风险因素的患者中.
- 需要进一步研究某些抗抑郁药的糖尿病效应背后的机制.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
303
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
303
Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
Antidepressant Drugs: Overview
357
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
357
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145

